Bristol Myers turns attention to new products in wake of Revlimid patent loss

AI · Bioregnum · Biotech Voices · Cell/Gene Tx · China · Coronavirus · Deals · Diagnostics · Discovery · FDA+ · Financing · Law · Letters to the …